Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Singapore ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while iShares MSCI Singapore ETF trades at $33.82. Which is the better fit depends on your goals.
| ABEO | EWS | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.45 | $33.92 |
52-Week Low | $4.17 | $26.71 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
EWS, the iShares MSCI Singapore ETF, trades at $33.64, up 1.42% and hitting a new 52-week high. Technical indicators show a bullish moving average trend but overbought oscillators. The ETF benefits from Singapore's economic resilience, AI-driven growth, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026.
Outlook is positive due to strong momentum and structural growth in Singapore's financial and tech sectors. Risks include concentrated exposure to financials (54% of holdings) and sensitivity to Asian market volatility. The ETF offers diversification but requires monitoring for overextension near all-time highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
